211 related articles for article (PubMed ID: 30474782)
1. The phosphodiesterase type 4 inhibitor roflumilast suppresses inflammation to improve diabetic bladder dysfunction rats.
Ding H; Zhang P; Li N; Liu Y; Wang P
Int Urol Nephrol; 2019 Feb; 51(2):253-260. PubMed ID: 30474782
[TBL] [Abstract][Full Text] [Related]
2. Treatment of obesity-associated overactive bladder by the phosphodiesterase type-4 inhibitor roflumilast.
Ding H; Li N; He X; Liu B; Dong L; Liu Y
Int Urol Nephrol; 2017 Oct; 49(10):1723-1730. PubMed ID: 28756610
[TBL] [Abstract][Full Text] [Related]
3. Anti-inflammation properties of resveratrol in the detrusor smooth muscle of the diabetic rat.
Xu F; Du H; Hou J; Liu J; Li N
Int Urol Nephrol; 2022 Nov; 54(11):2833-2843. PubMed ID: 35943662
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effect of roflumilast on experimental periodontitis.
Liu Q; Sun Y; Chen D; Chen K; Huang B; Chen Z
J Periodontol; 2022 Mar; 93(3):423-434. PubMed ID: 34124777
[TBL] [Abstract][Full Text] [Related]
5. Roflumilast prevents lymphotoxin α (TNF-β)-induced inflammation activation and degradation of type 2 collagen in chondrocytes.
Zhao J; Duan L; Wang R; Liu Y; Jiang J
Inflamm Res; 2020 Dec; 69(12):1191-1199. PubMed ID: 32990777
[TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterase-4 Inhibitor Roflumilast Attenuates Pulmonary Air Emboli-Induced Lung Injury.
Peng CK; Huang KL; Wu CP; Wu YK; Tzeng IS; Lan CC
J Surg Res; 2019 Sep; 241():24-30. PubMed ID: 31004869
[TBL] [Abstract][Full Text] [Related]
7. Roflumilast, a Phosphodiesterases-4 (PDE4) Inhibitor, Alleviates Sepsis‑induced Acute Kidney Injury.
Xu X; Liao L; Hu B; Jiang H; Tan M
Med Sci Monit; 2020 May; 26():e921319. PubMed ID: 32449901
[TBL] [Abstract][Full Text] [Related]
8. Roflumilast, a phosphodiesterase-4 inhibitor, improves hyperoxia-induced lung injury via anti-inflammation.
Cao HY; Yu TH; Han CH; Liu WW; Zhang PX; Tang P
Undersea Hyperb Med; 2020; 47(2):189-196. PubMed ID: 32574434
[TBL] [Abstract][Full Text] [Related]
9. PDE4 inhibition reduces neointima formation and inhibits VCAM-1 expression and histone methylation in an Epac-dependent manner.
Lehrke M; Kahles F; Makowska A; Tilstam PV; Diebold S; Marx J; Stöhr R; Hess K; Endorf EB; Bruemmer D; Marx N; Findeisen HM
J Mol Cell Cardiol; 2015 Apr; 81():23-33. PubMed ID: 25640159
[TBL] [Abstract][Full Text] [Related]
10. Effects of tadalafil (PDE5 inhibitor) and roflumilast (PDE4 inhibitor) on airway reactivity and markers of inflammation in ovalbumin-induced airway hyperresponsiveness in guinea pigs.
Mokry J; Urbanova A; Medvedova I; Kertys M; Mikolka P; Kosutova P; Mokra D
J Physiol Pharmacol; 2017 Oct; 68(5):721-730. PubMed ID: 29375047
[TBL] [Abstract][Full Text] [Related]
11. Dose dependent effects of tadalafil and roflumilast on ovalbumin-induced airway hyperresponsiveness in guinea pigs.
Urbanova A; Medvedova I; Kertys M; Mikolka P; Kosutova P; Mokra D; Mokrý J
Exp Lung Res; 2017; 43(9-10):407-416. PubMed ID: 29220595
[TBL] [Abstract][Full Text] [Related]
12. Effects of roflumilast, a phosphodiesterase-4 inhibitor, on hypoxia- and monocrotaline-induced pulmonary hypertension in rats.
Izikki M; Raffestin B; Klar J; Hatzelmann A; Marx D; Tenor H; Zadigue P; Adnot S; Eddahibi S
J Pharmacol Exp Ther; 2009 Jul; 330(1):54-62. PubMed ID: 19386793
[TBL] [Abstract][Full Text] [Related]
13. The effects of roflumilast on the pancreas and remote organs in a cerulein-induced experimental acute pancreatitis model in rats.
Uslukaya O; Turkoglu A; Yazgan UC; Kaplan I; Ibiloglu I; Kapan M; Gumus M
Surg Today; 2016 Dec; 46(12):1435-1442. PubMed ID: 26983712
[TBL] [Abstract][Full Text] [Related]
14. Effect of roflumilast, novel phosphodiesterase-4 inhibitor, on lung chronic graft-versus-host disease in mice.
Kim SW; Lim JY; Rhee CK; Kim JH; Park CK; Kim TJ; Cho CS; Min CK; Yoon HK
Exp Hematol; 2016 May; 44(5):332-341.e4. PubMed ID: 26898707
[TBL] [Abstract][Full Text] [Related]
15. BAY 11-7082 ameliorates diabetic nephropathy by attenuating hyperglycemia-mediated oxidative stress and renal inflammation via NF-κB pathway.
Kolati SR; Kasala ER; Bodduluru LN; Mahareddy JR; Uppulapu SK; Gogoi R; Barua CC; Lahkar M
Environ Toxicol Pharmacol; 2015 Mar; 39(2):690-9. PubMed ID: 25704036
[TBL] [Abstract][Full Text] [Related]
16. The selective phosphodiesterase 4 inhibitor roflumilast and phosphodiesterase 3/4 inhibitor pumafentrine reduce clinical score and TNF expression in experimental colitis in mice.
Rieder F; Siegmund B; Bundschuh DS; Lehr HA; Endres S; Eigler A
PLoS One; 2013; 8(2):e56867. PubMed ID: 23468885
[TBL] [Abstract][Full Text] [Related]
17. Phosphodiestrase-1 and 4 inhibitors ameliorate liver fibrosis in rats: Modulation of cAMP/CREB/TLR4 inflammatory and fibrogenic pathways.
Essam RM; Ahmed LA; Abdelsalam RM; El-Khatib AS
Life Sci; 2019 Apr; 222():245-254. PubMed ID: 30858122
[TBL] [Abstract][Full Text] [Related]
18. A phosphodiesterase 4 inhibitor, roflumilast N-oxide, inhibits human lung fibroblast functions in vitro.
Sabatini F; Petecchia L; Boero S; Silvestri M; Klar J; Tenor H; Beume R; Hatzelmann A; Rossi GA
Pulm Pharmacol Ther; 2010 Aug; 23(4):283-91. PubMed ID: 20226872
[TBL] [Abstract][Full Text] [Related]
19. Catechin Weakens Diabetic Retinopathy by Inhibiting the Expression of NF-κB Signaling Pathway-Mediated Inflammatory Factors.
Wang W; Zhang Y; Jin W; Xing Y; Yang A
Ann Clin Lab Sci; 2018 Sep; 48(5):594-600. PubMed ID: 30373863
[TBL] [Abstract][Full Text] [Related]
20. Combination of roflumilast with a beta-2 adrenergic receptor agonist inhibits proinflammatory and profibrotic mediator release from human lung fibroblasts.
Tannheimer SL; Wright CD; Salmon M
Respir Res; 2012 Mar; 13(1):28. PubMed ID: 22452977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
